Zymeworks Inc. (ZYME) stock
ZYMENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30141% above fair value
$26.47−2.60 (-8.94%)
Close on Nov 12, 2026Market cap $1.88BP/E 50.9Yield –
Zymeworks total assets
Total assets on the balance sheet at the end of each period.
Zymeworks's total assets was $1.18B at Sep 30, 2026. For fiscal 2025 it was $346.53M, down 25.2% from the year before. The highest annual figure on record is $648.73M in fiscal 2022.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $346.53M | -25.2% |
| FY2024 | Dec 31, 2024 | $463.09M | -20.3% |
| FY2023 | Dec 31, 2023 | $580.88M | -10.5% |
| FY2022 | Dec 31, 2022 | $648.73M | +66.7% |
| FY2021 | Dec 31, 2021 | $389.13M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.18B | +196.1% |
| Q2 FY2026 | Jun 30, 2026 | $396.96M | -2.8% |
| Q1 FY2026 | Mar 31, 2026 | $478.22M | +12.4% |
| Q4 FY2025 | Dec 31, 2025 | $346.53M | -25.2% |
| Q3 FY2025 | Sep 30, 2025 | $397.27M | -18.5% |
| Q2 FY2025 | Jun 30, 2025 | $408.39M | -20.8% |
| Q1 FY2025 | Mar 31, 2025 | $425.52M | -23.2% |
| Q4 FY2024 | Dec 31, 2024 | $463.09M | -20.3% |
| Q3 FY2024 | Sep 30, 2024 | $487.15M | -12.4% |
| Q2 FY2024 | Jun 30, 2024 | $515.63M | -14.4% |
| Q1 FY2024 | Mar 31, 2024 | $553.75M | -7.8% |
| Q4 FY2023 | Dec 31, 2023 | $580.88M | -10.5% |
| Q3 FY2023 | Sep 30, 2023 | $556.37M | +85.3% |
| Q2 FY2023 | Jun 30, 2023 | $602.05M | +54.7% |
| Q1 FY2023 | Mar 31, 2023 | $600.74M | – |
| Q4 FY2022 | Dec 31, 2022 | $648.73M | – |
| Q3 FY2022 | Sep 30, 2022 | $300.26M | – |
| Q4 FY2021 | Dec 31, 2021 | $389.13M | – |
See a number that looks wrong?